Updated results from ASCENT-J02, a study of sacituzumab govitecan in Japanese participants with metastatic triple-negative breast cancer
International Journal of Clinical Oncology · 14.11.2026
DOI: 10.1007/s10147-026-03214-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 14.11.2026. Verfasst von Nobuko Kawaguchi-Sakita und 15 weiteren Autor:innen. Beteiligte Einrichtung: Kyoto University Hospital, Kyoto, Japan. nobuko75@kuhp.kyoto-u.ac.jp. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Inc..
Abstract (Originalsprache)
Background
Sacituzumab govitecan (SG) is approved in Japan for pretreated unresectable or recurrent triple-negative breast cancer (TNBC). ASCENT-J02 is an open-label, phase 1/2 study of SG in Japanese patients. At primary analysis (median follow-up, 6.1 months) of the metastatic TNBC (mTNBC) cohort ( n = 36), objective response rate (ORR) was 25.0% (95% CI: 12.1–42.2; P = 0.0077), median progression-free survival (PFS) was 5.6 months (95% CI: 3.9–not reached), and SG had a manageable safety profile, consistent with the global phase 3 ASCENT study. We report updated outcomes, including the first overall survival (OS) results.
Methods
Patients with pretreated mTNBC received 10 mg/kg SG intravenously on days 1 and 8 of 21-day cycles. The primary endpoint was independent review committee-assessed ORR (RECIST v1.1). Secondary endpoints included PFS, duration of response, time to response, OS, and safety.
Results
With median follow-up of 15.9 months for 36 patients with mTNBC, ORR with SG was 31% (95% CI: 16–48); four complete responses were observed. Median PFS was 5.6 months (95% CI: 3.9–15.8), and median OS was 15.9 months (95% CI: 10.4–22.4). No treatment-emergent adverse events (TEAEs) led to treatment discontinuation or death. Grade ≥ 3 TEAEs were observed in 26 (72%) patients; most frequent were neutropenia (58%), leukopenia (36%), and diarrhea (11%).
Conclusions
With longer follow-up, SG continued to demonstrate efficacy and safety consistent with the global ASCENT study. These results further support the use of SG in Japanese patients with pretreated mTNBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kyoto University Hospital, Kyoto, Japan. nobuko75@kuhp.kyoto-u.ac.jp.
- National Cancer Center Hospital East, Kashiwa, Japan.
- Tohoku University Hospital, Miyagi, Japan.
- Osaka International Cancer Institute, Osaka, Japan.
- Kumamoto University Hospital, Kumamoto, Japan.
- Kyoto University Hospital, Kyoto, Japan.
Förderung
- Gilead Sciences, Inc.
Zitieren
APA
Kawaguchi-Sakita, N., Naito, Y., Ishida, T., Nakayama, T., Yamamoto, Y., Masuda, N., Matsumoto, K., Kogawa, T., Sudo, K., Shimomura, A., Lai, C., Shao, J., Iwahori, Y., Gary, D., Huynh, D., & Iwata, H. (2026). Updated results from ASCENT-J02, a study of sacituzumab govitecan in Japanese participants with metastatic triple-negative breast cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03214-9
Vancouver
Kawaguchi-Sakita N, Naito Y, Ishida T, Nakayama T, Yamamoto Y, Masuda N, et al. Updated results from ASCENT-J02, a study of sacituzumab govitecan in Japanese participants with metastatic triple-negative breast cancer. International Journal of Clinical Oncology. 2026. doi:10.1007/s10147-026-03214-9
BibTeX
@article{KawaguchiSakita2026,
author = {Kawaguchi-Sakita, Nobuko and Naito, Yoichi and Ishida, Takanori and Nakayama, Takahiro and Yamamoto, Yutaka and Masuda, Norikazu and Matsumoto, Koji and Kogawa, Takahiro and Sudo, Kazuki and Shimomura, Akihiko and Lai, Catherine and Shao, Jiang and Iwahori, Yuki and Gary, Dianna and Huynh, Danh and Iwata, Hiroji},
title = {Updated results from ASCENT-J02, a study of sacituzumab govitecan in Japanese participants with metastatic triple-negative breast cancer},
journal = {International Journal of Clinical Oncology},
year = {2026},
doi = {10.1007/s10147-026-03214-9}
}
EUVIMED